EMEA-002153-PIP01-17-M01

Key facts

Invented name
  • Trelegy Ellipta
  • Temybric Ellipta
  • Elebrato Ellipta
Active substance
  • fluticasone furoate
  • umeclidinium bromide
  • vilanterol trifenatate
Therapeutic area
Pneumology-allergology
Decision number
P/0058/2020
PIP number
EMEA-002153-PIP01-17-M01
Pharmaceutical form(s)
Inhalation powder, pre-dispensed
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
Inhalation use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited
Tel. +44 02089903650
E-mail: eu.paediatric-plans@gsk.com
Decision type
RPM: decision refers to a refusal on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating